 
CONFIDENTIAL  
This document is strictly confidential.  It was developed by [CONTACT_41482]. and should not be disclosed to a third party,  with the exception  of regulatory agencies and  study  
audit personnel. Reproduction, modification or adaptation, in part or in tot al, is strictly forbidden without prior written  approval by [CONTACT_41482].  
Throughout this document, symbols indicating proprietary names (®, TM) are not displayed. The appearance of product names wit hout these symbols does not imply that these  
names  are not protected.  
 
Clinical Evaluation of the Safety and Performance of  
Fractional Radiofrequency for the Treatment and 
Reduction of Acne Scarring  
 
STUDY SPONSOR  Venus Concept Inc. 
SPONSOR ADDRESS  [ADDRESS_43497]. Neil Sadick 
PROTOCOL 
VERSION  1.0 
PROTOCOL DATE  29th January  2021 
  
 
  
 
 CLINICAL STUDY 
PROTOCOL   
VI0121 
Venus VivaMD  
 
Venus Concept    
CONFIDENTIAL  Page 3 of 40      1.0                                     
January 29th, 2021 
 
Table of Contents 
PROTOCOL VERSION CONTROL  ........................................................................................................... 2 
sponsor approval/signature [CONTACT_3264]  ................................................................................................................... 6 
principal investigator [INVESTIGATOR_41473]/signature [CONTACT_3264] ............................................................................................. [ADDRESS_43498] OF ABBREVIATIONS ....................................................................................................................... 8 
STUDY SUMMARY .................................................................................................................................... 8 
SCHEMATIC OF STUDY DESIGN  ......................................................................................................... 10 
1 KEY ROLES  ................................................................................................................................... 10 
2  INTRODUCTION: BACKGROUND INFORMATION AND SCIENTIFIC RATIONALE  ........ 11 
2.1 Background Information ........................................................................................................ 11 
2.2 Rationale  ................................................................................................................................ 12 
2.3 Potential Risks and Benefits .................................................................................................. 12 
2.3.1 Known Potential Risks ......................................................................................... 12 
2.3.2 Known Potential Benefits .................................................................................... 12 
3 OBJECTIVES AND PURPOSE  ..................................................................................................... 13 
4 STUDY DESIGN AND ENDPOINTS  ........................................................................................... 13 
4.1 Description of the Study Design  ............................................................................................ 13 
4.2.1 Primary Endpoint ................................................................................................. 13 
4.2.2 Secondary Endpoints ........................................................................................... 13 
4.2.3 Exploratory Endpoints ......................................................................................... 13 
5 STUDY ENROLLMENT AND WITHDRAWAL  ......................................................................... 13 
5.1 Participant Inclusion Criteria  ................................................................................................. 13 
5.2 Participant Exclusion Criteria  ................................................................................................ 14 
5.3 Strategies for Recruitment and Retention  .............................................................................. 14 
5.4 Participant Withdrawal or termination  .................................................................................. 15 
5.4.1 Reasons for Withdrawal or Termination .............................................................. 15 
5.4.2 Handling of Participant Withdrawals or termination ........................................... 15 
5.5 Premature Termination or Suspension of Study .................................................................... 15  
6 INVE
STIGATIONAL DEVICE  ..................................................................................................... 16 
6.1 Investigational device and Control Description ..................................................................... 17 
6.1.1 Acquisition ........................................................................................................... 17 
6.1.2 Device Specific Considerations  ........................................................................... 17 
6.2 Investigational device Accountability Procedures  ................................................................. 17 
7.1 Study Procedures/Evaluations ............................................................................................... 17 
7.1.1 Study specific procedures .................................................................................... 17 
7.2 Laboratory Procedures/Evaluations ....................................................................................... 17 
7.2.1 Clinical Laboratory Evaluations .......................................................................... 18 
7.3 Study Schedule ...................................................................................................................... 18 
7.3.2 Enrollment/Baseline/SCREENING  ..................................................................... 18 
7.3.2 Baseline Visit  ....................................................................................................... 18 
7.3.3 Treatm ent Visits  ................................................................................................... 19 
7.3.3 Follow-up ............................................................................................................. 21 
 CLINICAL STUDY 
PROTOCOL   
VI0121 
Venus VivaMD  
 
Venus Concept    
CONFIDENTIAL  Page 4 of 40      1.0                                     
January 29th, 2021 
 
7.3.5 Early Termination Visit  ....................................................................................... 21 
7.3.7 Schedule of Events Table  .................................................................................... 21 
7.4 Justification for Sensitive Procedures .................................................................................... 22 
7.5 Concomitant Medications, Treatments, and Procedures ........................................................ 22 
7.6 Prohibited Medications, Treatments, and Procedures  ............................................................ 22 
7.7 Prophylactic Medications, Treatments, and Proced ures ........................................................ 23 
7.8 Rescue Medications, Treatments, and Procedures  ................................................................. 23 
8 ASSESSMENT OF SAFETY  ......................................................................................................... 23 
8.1 Specification of Safety Parameters ........................................................................................ 23 
8.1.1 Definition of Adverse Events (AE)...................................................................... 23 
8.1.2 Definition of Serious Adverse Events (SAE) ...................................................... 24 
8.1.3 Definition of Unanticipated Problems (UP)  ........................................................ 24 
8.1.4 Definition of Device deficiency  ........................................................................... 24 
8.2 Classification of an Adverse Event  ........................................................................................ 25 
8.2.1 Severity of Event ................................................................................................. 25 
8.2.2 Relationship to Study Agent ................................................................................ 25 
8.2.3 Expectedness ........................................................................................................ 26 
8.3 Time Period and Frequency for Event Assessment and Follow- Up ...................................... 26 
8.4 Reporting Procedures ............................................................................................................. 27 
8.4.1 Adverse Event Reporting ..................................................................................... 27 
8.4.2 Serious Adverse Event Reporting ........................................................................ 27 
8.4.5 Reporting of Pregnancy  ....................................................................................... 28 
8.5 Study Halting Rules ............................................................................................................... 28 
8.6 Safety Oversight .................................................................................................................... 28 
9 CL INICAL MONI TORING ............................................................................................................ 28 
10 STATISTICAL CONSIDERATIONS  ............................................................................................ 29 
10.1 Statistical and Analytical Plans .............................................................................................. 29 
10.2 Statistical Hypotheses  ............................................................................................................ 29  
10.3 Anal
ysis Datasets  ................................................................................................................... 29 
10.4 Description of Statistical Methods  ......................................................................................... 30 
10.4.1 General Approach ................................................................................................ 30 
10.4.2 Analysis of the Primary Efficacy Endpoint(s) ..................................................... 30 
10.4.3 Analysis of the Secondary Endpoint(s)................................................................ 31 
10.4.4 Safety Analyses.................................................................................................... 31 
10.4.5 Adherence and Retention Analyses ..................................................................... 32 
10.4.6  Baseline Descriptive Statistics  ............................................................................. 33 
10.4.7 Planned Interim Analyses .................................................................................... 33 
10.4.10 Tabulation of Individual Response Data.............................................................. 33 
10.5 Measures to Minimize Bias  ................................................................................................... 33 
10.5.1 Enrollment/ Randomization/ Masking Procedures .............................................. 33 
10.5.2 Evaluation of Success of Blinding ....................................................................... 33 
11 SOURCE DOCUMENTS AND ACCESS TO SOURCE DATA/DOCUMENTS  ......................... 34 
 CLINICAL STUDY 
PROTOCOL   
VI0121 
Venus VivaMD  
 
Venus Concept    
CONFIDENTIAL  Page 5 of 40      1.0                                     
January 29th, 2021 
 
12 QUALITY ASSURANCE AND QUALITY CONTROL  .............................................................. 34 
13 ETHICS/PROTECTION OF HUMAN SUBJECTS ....................................................................... [ADDRESS_43499] .................................................................................................... 35 
13.3 Informed Consent Process ..................................................................................................... 35 
13.3.1 Consent/assent and Other Informational Documents Provided to Participants  ... [ADDRESS_43500] POLICY  ............................................................................................ 39 
17  LITERATURE REFERENCES ...................................................................................................... 39 
APPENDIX  ................................................................................................................................................. 40 
 
  
 CLINICAL STUDY 
PROTOCOL   
VI0121 
Venus VivaMD  
 
Venus Concept    
CONFIDENTIAL  Page 6 of 40      1.0                                     
January 29th, 2021 
 
SPONSOR APPROVAL/SIGNATURE [CONTACT_41499], acts and regulations, the 
ethical pricinples that have their origins in the Declaration of Helsinki and all amendments, GCP 
requirements , ISO [ZIP_CODE]:2011 (Clinical Investigation of Medical Devices for Human Subjects – Good 
Clinical Practice), Medical Devices Directive 93/42/EEC, MEDDEV 2.7/3, ICH guidance E6 on Good Clinical Practice, and any applicable regional or national regulations pertaining to the conduct of clinical 
investigation of a medical device . 
 
 
 
 
Sponsor Representative  
 
 
 
 
 
  
 
Signa
ture ______________________________________ Date __________________ 
  

 Version 1.[ADDRESS_43501]  
ISO [ZIP_CODE]:[ADDRESS_43502]  
VAS  Visual Analog Scale  
 
STUDY  SUMMARY  
 
Study Title  Clinical Evaluation of the Safety and Performance of Fractional 
Radiofrequency for the Treatment and Reduction of Acne Scarring 
Protocol Number VI0121 - Protocol Version: 1.0, 29January2021 
Objectives The objective of this clinical study is to evaluate the safety and 
performance of FRF  for the treatment and reduction of acne scarring.  
Study Design  Non-randomized, single center, 3- treatment sessions, evaluator -blinded 
study using the Venus VivaTM MD. 
Treatment Regimen  The study will involve up to 3 Venus VivaTM MD treatments with 4 -week 
(±7 days) intervals between each treatment. Subjects will receive treatment 
according to the parameters specified in the Methods section.  
 Version 1.0 
Protocol  VI0121 29th January  2021  
Venus Concept    
CONFIDENTIAL  Page 9 of 40      1.0                                     
January 29th, 2021 
 Return/Follow -up 
Visits  Subjects will be followed at [ADDRESS_43503] treatment.   
 
Adverse Events and any changes to concomitant medications will be 
recorded. Subjects will complete a Patient S atisfaction questionnaire.  
Investigator will complete a Global Aesthetic Improvement Scale. 
Photographs of the treated area will be taken. 
Study Subjects  Up to 20 (male and non- childbearing female) subjects requesting treatment 
of moderate to severe acne scars in Fitzpatrick skin types I -IV. Up to [ADDRESS_43504] skin biopsies taken for histological analyses. 
Methods  • Histologic samples will be taken immediat ely after the first 
treatment and at final follow -up visit.  
• Standardized photographic images will be taken at the baseline 
visit, and at each Follow Up Visit ([ADDRESS_43505] final 
treatment).  
• Standardized photographs will be assessed by [CONTACT_41483] (GAIS).  
Endpoints  Primary performance endpoints  
• Improvement in acne  scarring  at [ADDRESS_43506]-
treatment  compared  to baseline as assessed  by [CONTACT_41484] 
• Subjects’ assessment of satisfaction with the treatment using a Subject  Satisfaction Scale at [ADDRESS_43507]- treatment.  
 
Safety endpoints 
• Subject’s assessment of discomfort and pain after treatments as measured by a 10 cm visual analog scale (VAS) and Tolerability Scale  
• Subjects experiencing a treatment -related adverse eve nt (AE) by [ADDRESS_43508] ive of this clinical study is to evaluate the safety and performance of fractional RF for the 
treatment of  acne scarring .  
The use of the Venus Viva™ MD has been determined to present non-significant risk in accordance with 
21 CFR 812.3 for the intended use in this study, because the device is not:  
• Intended as an implant; 
• Purported or represented to be for use supporting or sustaining human life; 
• Substantial importance in diagnosing, curing, mitigating, or treating disease, or otherwise 
preventing impairment of human health  
• Otherwise presenting a potential for serious risk to the health, safety, or welfare of a subject.  
This study will be conducted in compliance with the protocol and according to Good Clinical Practice 
(GCP) standards.  
2.[ADDRESS_43509]- treatment, excessive skin redness (erythema) and/or swelling (edema),  in-grown 
hairs, damage to natural skin texture (crust, blister, burn), change of pi[INVESTIGATOR_371] (hyper- and hypo-
pi[INVESTIGATOR_371]) and scarring. Treatment of hair -bearing areas in male patients may result in some damage 
to the follicles and subsequent loss of h air.  Avoid the beard area and other hair - growing zones if the 
patient does not wish to experience hair growth reduction.  
Further information about residual risks associated with the device and with participation in the clinical 
investigation are reporte d in the device User Manual.  
Residual risks will be mitigated as follows:  
− Selection of an investigator with experience in the therapeutic area of the clinical investigation 
− Investigator and site staff will have already undergone training prior to patients’ enrollment 
− Prior to the first procedure, the investigator and site staff will undergo a re-training session by [CONTACT_41485]  
− Patients will be rigorously screened prior to their enrollment  
− Patients will be rigorously followed over the course of the study 
 
2.3.[ADDRESS_43510] agrees to participate in this study, he/she will be contributing to the understanding of the 
device’s impact and the biological processes that are occurring regarding acne scar formation. This understanding may lead to optimization of the treatment with this device for these indications.  In 
addition, the subject may benefit from improvement in acne scar appearance in the treated areas.  
3 OBJECTIVES AND  PURPOSE  
This clinical study is being conducted to evaluate the safety and performance of fractional RF for the 
treatment and reduction of acne scarring. Total expected duration of the clinical investigation is eight months (enrolment period of 2 months, follow-up period of 6 months), while individual subject 
participation will take approximately 6 months. 
4 STUDY DESIGN AND ENDPOINTS  
 
4.1 DESCRIPTION OF THE STUDY DESIGN  
This is a prospective, ev aluator -blind study of the safety and performance of fractional RF for the 
treatment and reduction of acne scarring. 
4.2.1 PRIMARY ENDPOINT  
• Improvement in acne scarring at [ADDRESS_43511]-intervention compared to baseline as assessed by [CONTACT_41486] (GAIS) for acne scarring. 
4.2.2 SECONDARY ENDPOINTS  
• Subjects’ assessment of satisfaction with the treatment using a Subject Satisfaction Scale  at [ADDRESS_43512] -treatment.  
4.2.3 EXPLORATORY ENDPOINTS  
• Subjects’ assessment of discomfort and pain after treatments as measured by a 10 cm visual analog scale (VAS).  
• Subjects experiencing a treatment -related adverse event (AE) by [ADDRESS_43513]- treatment.  
5 STUDY ENROLLMENT AND WITHDRAWAL  
 
5.1 PARTICIPANT  INCLUSION CRITERIA  
1. Healthy, male or female subjects over 21 years of age who are seeking treatment an d reduction of 
their acne scarring.  
2. Able to read, understand and voluntarily provide written Informed Consent. 
3. Able and willing to comply with the treatment/follow -up schedule and requirements. 
 Version 1.[ADDRESS_43514] at baseline. 
5.2 PARTICIPANT EXCLUSION CRITERIA  
1. Implantable defibrillators, cardiac pacemakers, and other metal implants  
2. Subjects with any implantable metal device in the treatment area  
3. Pacemaker or internal defibrillator, or any other active electrical implant anywhere in the body (e.g. cochlear implant).  
4. Permanent implant in the treated area, such as metal plates and screws, or an injected chemical 
substance. 
5. Current or history of any kind of cancer, or pre- malignant moles.  
6. Severe concurrent conditions, such as cardiac disorders.  
7. Pregnancy or intending to become pregnant during the study and nursing. 
8. Impaired immune system due to immunosuppressive diseases, such as AIDS and HIV, or use of immunosuppressive medications.  
9. History of diseases stimulated by [CONTACT_10388], such as recurrent herpes simplex in the treatment area; may be enrolled only after a prophylactic regime has been followed for 2 weeks or longer prior to 
enrollment, or according to Investigator’s discretion. 
10. Poorly controlled endocrine disorders, such as diabetes. 
11. Any active condition in the treatment area, such as sores, psoriasis, eczema, and rash. 
12. History of skin disorders, such as keloids, abnormal wound healing, as well as very dry and 
fragile skin.  
13. History of bleeding coagulopathies, or use of anticoagulants (excluding daily aspi[INVESTIGATOR_248]). 
14. Facial dermabrasion, facial resurfacing, or deep chemical p eeling within the last three months, if 
face is treated.  
15. Use of isotretinoin (Accutane®) or other systemic retinoids within six months or topi[INVESTIGATOR_41474]; or as per physician’s discretion.  
16. Use of non- steroidal anti-inflammatory drugs (NSAIDS, e.g. ibuprofen-containing agents) one 
week before and after each treatment session.  
17. Any surgical procedure in the treatment area within the last six months or before complete 
healing. 
18. Treating over tattoo or permanent makeup. 
19. Excessively tanned skin from sun, tanning beds or tanning creams within the last two weeks. 
20. As per the practitioner's discretion, refrain from treating any condition which might make it unsafe for the patient.  
5.[ADDRESS_43515] been treated according to the study protocol.  It is 
anticipated that it will take up to eight months to complete the study.  Subjects will  primarily be recruited from the investigator’s practice.  Any advertising campaigns and materials will be reviewed and approved 
by [CONTACT_41487] (EC or IRB) before implementa tion. Due to the 
 Version 1.[ADDRESS_43516] drops out of the study or is withdrawn from the study, the End of Study/Early 
Discontinuation CRF form should be completed.  On the discontinuation page, the Investigator should 
record the date of the withdrawal and the reason for withdrawal.  
Reasonable effort should be made to contact [CONTACT_41488].  The records of subjects who 
terminate prior to completing the study will be retained and the reason for termination will be 
documented. 
The investigator may terminate participation in the study if:  
• Any clinical adverse event (AE), laboratory abnormality, or other medical condition or situation 
occurs such that continued participation in the study would not be in the best interest of the 
subject. 
• The subject meets an exclusion criterion (either newly developed or not previously recognized) 
that precludes further study participation. 
5.4.[ADDRESS_43517] an exit visit (final study visit, see section 7.3.5) to 
withdrawn patients, and to undertake protocol- specified safety follow -up procedures to capture AEs, 
serious adverse events (SAEs) and device deficiencies.  
5.5 PREMATURE TERMINATION OR SUSPENSION  OF STUDY  
The sponsor may suspend or prematurely terminate this study at the investigation site for significant and 
documented reasons.  
 
A principal investigator, EC/IRB, or regulatory authority may suspend or prematurely terminate 
participation in the stu dy at the investigation site for which they are responsible. 
 
If suspi[INVESTIGATOR_10366], or when so instructed by [CONTACT_1383]/IRB or regulatory authorities, the sponsor shall suspend the clinical investigation whil e the risk is assessed.  The 
sponsor shall terminate the study if an unacceptable risk is confirmed.  
 
 Version 1.[ADDRESS_43518] communica tion. The principal investigator 
[INVESTIGATOR_41475]/IRB or the 
regulatory authority.  
 
If, for any reason, the sponsor suspends or prematurely terminates the study at the investigation site, the 
sponsor shall inform the responsible regulatory authority as appropriate and ensure that the EC/IRB is notified, either by [CONTACT_458] [INVESTIGATOR_10368].  If the suspension or premature termination 
was in the interest of safety, t he sponsor shall inform all other principal investigators. 
 
If suspension or premature termination occurs,  
a) the sponsor shall remain responsible for providing resources to fulfil the obligations from the 
clinical investigative plan and existing agreements f or following up the subjects enrolled in the 
study, and 
b) the principal investigator [INVESTIGATOR_41476], if appropriate  
 
In case of early termination, final study activities according to the protocol, including the follow up visits 
and procedures to assess the safety and efficacy of the device will be conducted, regardless of the sponsor's interest in the study.  Follow -up activities will be conducted so that device deficiencies can be identified 
and appropriate safety measures can be implemented.  
 
At the completion or termination of the study, the Investigator will return all remaining clinical supplies to 
Sponsor along with a copy of the device supply and inventory records.  Circumstances that may warrant termination or suspension include, but are not limited to:  
• Determination of unexpected, significant, or unacceptable risk to participants (examples of findings that might trigger a safety review are the number of SAEs overall , the number of 
occurrences of a particular type of SAE, severe AEs/reactions, or increased frequency of events – 
refer to section 8.5 STUDY HALTING RULES.  
• Demonstration of performance that would warrant stoppi[INVESTIGATOR_007] 
• Insufficient compliance to protocol require ments  
• Data that are not sufficiently complete and/or evaluable 
• Determination of futility  
Study may resume once concerns about safety, protocol compliance, data quality are addressed and 
satisfy the sponsor, EC / IRB and/or regulatory authorities. 
6 INVESTI GATIONAL DEVICE  
 
 Version 1.0 
Protocol  VI0121 29th January  2021  
Venus Concept    
CONFIDENTIAL  Page 17 of 40      1.0                                     
January 29th, 2021 
 6.1 INVESTIGATIONAL DEVICE AND CONTROL DESCRIPTION  
 
6.1.1  ACQUISITION  
If the investigative site does not own a Venus Viva™ MD, a device will be provided by [CONTACT_456].  An 
activation code will be required to activate the device (not applicable if the site owns the device).  This 
code will be provided to the investigative site once all regulatory and EC/IRB approvals are in place and the site has received training for both the device and the study (if applicable).  
6.1.2  DEVICE SPECIFIC CONSIDERATIONS  
• Device model(s) - Venus Viva™ MD 
• Device settings and programming – Ablation and Coagulation Mode; 180-280 volts, 5-30 ms 
pulse dura tion 
• Duration of exposure and frequency –   
o For all subjects - monthly treatment for 3 months.   
The Venus Viva™ MD is a non- invasive medical aesthetic device, intended for use in dermatologic and 
general surgical procedures, requiring ablation and resurfacing of the skin, using the Viva applicator.   
The system consists of a handheld applicator with disposable tips. The tip options include an 80 pin  tips, 
8x20 mm in size, that delivers the Multi Polar Radiofrequency (RF) to the skin.  Further details about the 
Venus Viva™ MD can be found in the device User Manual.  
6.2 INVESTIGATIONAL DEVICE ACCOUNTABILITY PROCEDURES  
If the device is supplied by [CONTACT_456], traceability shall be achieved during and after the clinical 
investigation by [CONTACT_41489].  Disposal tips will be provided by [CONTACT_456].  
7.1 STUDY PROCEDURES/EVALUATIONS  
7.1.1 STUDY SPECIFIC PROCEDURES  
The following procedures and evaluations will be done as part of the study: 
Demographics  
Medical /surgical history (obtained by [CONTACT_10393]/or medical records)  
Physical examination  
Assessment of eligibility  
Photographs  
Blinded assessment  
Administration of questionnaires and scales for blinded reviewer and patient- reported outcomes  
Adverse event recording  
Concomitant medications  
7.2 LABORATORY PROCEDURES/EVALUATIONS  
 Version 1.[ADDRESS_43519] to be performed within 24 hours of study intervention with results available prior to 
administration of treatment.    
 For up to 10 subjects, histological samples of a separate treated area will be obtained at baseline, 
immediate/post procedure, [ADDRESS_43520] UDY SCHEDULE  
 
7.3.2  ENROLLMENT/BASELINE/SCREENING  
 
Screening Visit and Enrolment (Day -7 to - 2) 
If the subject meets the preliminary study criteria, the study doctor, and/or his/her designee, will obtain an 
informed consent from the subject prior to any study procedure, clearly indicating his/her understanding 
of the requirements and possible risks associated with study participation and other applicable treatment 
options.  Subjects will receive a unique identifying number that will be composed of a two- digit site 
number and a two-digit subject number in sequence.  This unique identifier will be used throughout the 
entire study and will be entered in the subject's case report form (CRF).  
During the first visit, the study investigator, and/or his/her designee, will screen the subject for eligibility 
to participate in the clinical study using the inclus ion/exclusion criteria.  A negative urine pregnancy test 
will be obtained (in patients of child-bearing potential).  During screening, the study doctor will review the subject's medical/surgical history, demographics, physical exam and examine the subject' s targeted 
treatment area to ensure that it meets the study criteria.  The subject will complete screening and the 
treatment will be scheduled.  
Test Spots  
A small test spot will be performed in a non- conspi[INVESTIGATOR_10370], prior to the first 
complete session. Test spots are performed to establish the following requirements: 
• Confirm the patient's suitability for treatment:  
o For skin types I- III, wait 24 -48 hours  
o For skin type IV- VI, wait 5 – 7 days before assessing the skin response  
• Establ ish and confirm treatment parameters:  If the desired endpoint of erythema and edema – in 
a tip-shaped pattern – has not been achieved within 10- [ADDRESS_43521] spot whenever changing parameters.  
7.3.2  BASELINE VISIT  
Baseline Visit (Visit 1 – Day 0) 
Subjects will return to the clinic within [ADDRESS_43522] of three treatments (see 7.3.3).  The subject’s eligibility status at this timepoint according to the 
 Version 1.0 
Protocol  VI0121 29th January  2021  
Venus Concept    
CONFIDENTIAL  Page 19 of 40      1.0                                     
January 29th, 2021 
 inclusion/exclusion criteria will be re -confirmed.  Test spot assessment, photographs, AEs and any 
changes to concomitant medications will be recorded. For patients who volunteer to receive a biopsy for 
histological assessment, a punch biopsy of an untreated area will be obtained. This separate assessment area for the biopsy may be designated to a non- conspi[INVESTIGATOR_41477].  
7.3.3  TREATMENT VISITS  
Beginning with the Baseline visit (Visit 1), subjects will receive a total of 3 treatments approximately 3 -5 
weeks apart.  The left and right side of the face will be treated and assessed as independent sites, and the 
same appli cator tip configuration will be used to treat both sides at all 3 treatment visits.  Adverse events 
and any changes to concomitant medications will be recorded at these visits. 
Subjects will receive treatment as described below.  Following treatment, the investigator will examine 
the treated area and report immediate and short term response.  Subjects will complete the 10 cm 
discomfort/pain VAS and Tolerability Scale immediately after treatment.   
The investigator will examine the treated areas and report immediate and short term response ([ADDRESS_43523]-treatment) (pain during treatment, hemorrhage, burn, erythema, edema, purpura) using a 5- point 
scale: 1=none; 2=trace; 3=modera te; 4=marked; 5=severe.   
The normal response to these treatments is transient erythema and edema. If any other side effects occur, as indicated in the protocol, they must be recorded. 
Visit 1 – Day [ADDRESS_43524]- treatment.   
Histology Visit – Week 1 (+/ - 7 days) 
Patients who volunteer to the Histological assessment subgroup are to return to the clinic for the Week 1 
biopsy. A punch biopsy of the separate treated area will be obtained at this visit. In addition to the biopsy, any AEs or changes to concomitant medications will be recorded. 
Visit 2 – Week 4 (+/ - 7 days) 
The Subject is to return to the clinic for their second of the three treatments.  In addition to the treatment, 
concomitant medications,  AEs and the pain VAS and Tolerability Scale are to be completed by [CONTACT_102].  
Visit 3 --  Week 8 (+/ - 7 days) 
The Subject is to return to the clinic for their final treatment.  In addition to the treatment, concomitant medications,  AEs and the pain VAS and Tolerability Scale a re to be completed by [CONTACT_102].  
Treatment  
Subjects will be asked to present to the clinic clean shaven prior to receiving treatment.  There should be 
no lotion, make-up, perfume, powder, or bath/shower oil present on the skin in the area to be treated. 
 Version 1.0 
Protocol  VI0121 29th January  2021  
Venus Concept    
CONFIDENTIAL  Page 20 of 40      1.0                                     
January 29th, 2021 
 Ensure that the skin is completely dry during the entire treatment. If the skin moistens during treatment 
(i.e. perspi[INVESTIGATOR_1516], etc.) re-wipe the skin with an alcohol pad and ensure that the skin is completely dry 
before continuing the treatment. 
Depending upon the subject’s sensitivity to the test spot administration, a topi[INVESTIGATOR_41478]’s discretion.  This 
topi[INVESTIGATOR_41479].  
Set the treatment parameters to desired treatment mode . The selected 80 pin tip will be utilized for all of 
the specific patient’s subsequent treatments. Set the desired energy level according to the skin type, 
severity of the treated condition, treatment area, bone proximity, etc. Set conservative parameters from a test spot for the first treatment, and then gradually increase during treatment or in subsequent treatments 
according to the desired impact and test sp ot results.  
To perform the treatment, place the tip on the target zone, perpendicular to the skin surface and with full 
contact [CONTACT_8124].  Emit a pulse by [CONTACT_10394]'s trigger; this will create a tip -shaped 
pattern on the patient's skin t hat will appear 1 -2 minutes later. Move the applicator to an adjacent spot on 
the skin overlappi[INVESTIGATOR_10373] 10% and emit another pulse (not applicable to the test spot). There should be no untreated gaps between the pulses.  
Examine the treated area. The immediate responses, indicative of the desired effect, are erythema and 
edema in the immediate area of the tip -shaped pattern and possibly also around it. The edema usually 
appears 1 -2 minutes after pulsing and reaches its peak (of up to moderate edema) within 30 minutes. It 
should be noted that erythema is not easily noticeable – if at all – in darker skin types. Therefore, the 
edema will be more prominent in these patients. After completing a full pass on the entire treatment area, 
if untreated patches of skin are apparent, re- treat these patches as per the following procedure:  
i. Wipe the untreated patch of skin with a dry gauze pad. 
ii. Treat the untreated patches of skin as normally.  
Fine-tuning of the parameters should be done before proceeding to treatment o f the entire sub -area with 
the selected parameters. The applicator tip should be placed on the skin, a pulse emitted, then lifted and 
moved to an adjacent spot of the skin. The emitted pulses should create tip -shaped patterns. Leave, no 
untreated gaps between the pattern marks, while also being careful not to overlap the treated zones. The 
parameters can be modified during subsequent visits, as per the practitioner's discretion. 
Post-Treatment Care 
Post-treatment cooling is not necessary.  In the event of p ost-treatment discomfort, it is recommended to 
cool the treated area immediately with air cooling.  Cold (not frozen) packs may also be used. Blistered or 
ulcerated skin can be treated with a prescribed cream. Tiny scabs of less than [ADDRESS_43525] -treatment and may remain for several days. The scabs should not be touched or 
scratched even if they itch, and should be allowed to shed off naturally. Blistered or ulcerated skin can be 
treated with a prescribed antibiotic ointm ent or burn treatment cream as per physician's discretion.  
During the first two days following treatment, care should be taken to prevent trauma to the treated site.  
Hot baths, massage, etc. should be avoided. The skin should be kept clean to avoid contamination or 
infection.  Any mechanical or thermal damage to the area must be avoided.  Moisturizer may be applied 
only 24 hours after each treatment, and then should be applied regularly throughout the course of the 
treatment.  Make- up may be applied only 24 hours after each treatment if desired, unless an unwanted 
reaction occurs in the area.  Generally, 24 hours after treatment, patients may use regular soaps, but not 
scrub soaps or exfoliants. The patient should use a high- factor sunscreen (at least 30 S PF) and protect the 
treated area from sunlight for at least one month after the treatment.  Tanning of any sort (sun exposure, 
 Version 1.0 
Protocol  VI0121 29th January  2021  
Venus Concept    
CONFIDENTIAL  Page 21 of 40      1.0                                     
January 29th, 2021 
 tanning beds, and artificial sunless tanning lotions) is not allowed in the treated areas during the entire 
course of the treatment.  Tanning after treatment may cause hyperpi[INVESTIGATOR_371].  
Photography 
Photographs will be taken prior to first treatment and throughout the study according to specified time points detailed in the Schedule of Events Table (section 7.3.7), utilizing standard scientific equipment.     
The photos should be taken in a private room or area of the clinic under controlled conditions, including 
the distance, angle, background and lighting in order to achieve high-quality sets of photographs.   The 
subject should be placed in the same position each time.  As each photograph is taken, it should be 
viewed to ensure that it is in focus and is similar to its baseline counterpart in all technical aspects, 
including lighting, distance and angle. 
For consistency purposes, the same person should ideall y take all study photographs, especially per 
subject.  The digital files should follow a consistent standard naming scheme.  
7.3.3  FOLLOW -UP  
Visit 4 – [ADDRESS_43526] Final Treatment (+/- 7 days) 
Subjects will return to the clinic [ADDRESS_43527] Satisfaction Scale and 
Treatment Evaluation Questionnaire.  
Photographs of the treated area will be taken as described in section 7.3.3. The photographs will be sent to 
the blinded independent reviewer for the Global Aesthetic Improvement Scale (GAIS) assessment.   
Visit 5 – [ADDRESS_43528] Final Treatment (+/- 7 days) 
Subjects will return to the clinic for a final study  visit [ADDRESS_43529] all reportable events wi th start dates occurring any time after informed consent is obtained until 7 
(for non -serious AEs) or 30 days (for SAEs) after the last day of study participation. 
7.3.[ADDRESS_43530] degree burn or 
pain beyond narcotics, then the following procedure will be implemented: 
• Immediate triage and treatment of the patient shall be determined by [CONTACT_41490].  
• The event will be reported to the sponsor study Director within [ADDRESS_43531] be reported on the SAE form. 
• An anonymized copy of the patient chart and treatment parameters are to be forwarded to the sponsor study Director within 24 hours.   
The sponsor study Director will be responsible for issuing a written report to the company and the EC or IRB Chairman no later than 7 days from the event   
Long term follow up and care shall continue at the discretion of the treating physician.  
All patients experiencing a complication of the device will be followed a minimum of 2 years following 
the initial injury.  Longer care and observation will be at the discretion of the treating physician.   
All minor complicatio ns such as appearance or altered sensation, except for pain, can be reported within 
30 days of patient complaint.  Both chart and treatment parameters are to be provided to the study 
Director and shared with the company and EC or IRB chairman.  
8 ASSESSMEN T OF SAFETY  
 
8.1 SPECIFICATION OF SAFETY PARAMETERS  
In addition to spontaneous reports of adverse events, subjects will complete a 10 cm discomfort/pain VAS, Tolerability Scale and the principal investigator [INVESTIGATOR_41480]. 
8.1.1 DEFINITION OF ADVERSE EVENTS  (AE)  
Adverse event means any untoward medical occurrence, unintended disease or injury, or untoward clinical signs (including abnormal laboratory findings) in subjects, users or other persons, whether or not 
related to the investigational medical device.  This d efinition includes events related to the investigational 
medical device or the comparator. This definition includes events related to the procedures involved.  For 
 Version 1.0 
Protocol  VI0121 29th January  2021  
Venus Concept    
CONFIDENTIAL  Page 24 of 40      1.0                                     
January 29th, 2021 
 users or other persons, this definition is restricted to events related to investigational m edical devices (ISO 
[ZIP_CODE]:2011). 
Adverse device effect means any adverse event related to the use of an investigational medical device. 
This definition includes adverse events resulting from insufficient or inadequate instructions for use, deployment, impl antation, installation, or operation, or any malfunction of the investigational medical 
device. This definition includes any event resulting from use error or from intentional misuse of the 
investigational medical device (ISO [ZIP_CODE]:2011).  
8.1.2 DEFINITION OF SERIOUS ADVERSE EVENTS  (SAE)  
NOTE: The term serious is not synonymous with severity, which may be used to describe the intensity of 
an event experienced by [CONTACT_423]).  An AE that does not meet any of the below criteria will be classified a s non- serious.  
A serious AE is any adverse event that:  
• led to death,  
• led to serious deterioration in the health of the subject, that either resulted in 
− a life -threatening illness or injury, or  
− a permanent impairment of a body structure or a body function, or  
− in-patient or prolonged hospi[INVESTIGATOR_059], or 
− medical or surgical intervention to prevent life -threatening illness or injury or permanent 
impairment to a body structure or a body function, 
• led to fetal distress, fetal death or a congenital abnormality or birth defect  
Planned hospi[INVESTIGATOR_272] a pre -existing condition, or a procedure required by [CONTACT_10396], without serious 
deterioration in health, is not considered a serious adverse event (ISO [ZIP_CODE]:2011). 
8.1.3 DEFINITION OF UNANTICIPATED PROBLEMS  (UP)  
This definition includes any adverse device effect that has resulted in any of the consequences 
characteristic of a serious adverse event.  Unanticipated serious adverse device effect ([LOCATION_003]DE) is any serious adverse device effect which by [CONTACT_5942], incidence,  severity or outcome has not been identified in 
the current version of the risk analysis report.  Anticipated serious adverse device effect (ASADE) is an 
effect which by [CONTACT_5942], incidence, severity or outcome has been identified in the risk analysis re port 
(ISO14155:2011). 
8.1.[ADDRESS_43532] to its identity, quality, durability, reliability, safety or 
performance. Device deficiencies include malfunctions, use errors, and inadequate labelling (ISO 
[ZIP_CODE]:2011). 
Any Investigational Medical Device Deficiency that might have led to a SAE if a) suitable action had not 
been taken or b) intervention had not been made or c) if circumstances had been less fortunate is subject to the same reporting requirement of SAEs (MEDDEV 2.7/3 revision 3). 
 Version 1.0 
Protocol  VI0121 29th January  2021  
Venus Concept    
CONFIDENTIAL  Page 25 of 40      1.0                                     
January 29th, 2021 
 8.2 CLASSIFICATION OF AN ADVERSE EVENT  
 
8.2.1 SEVERITY OF EVENT  
For AEs not included in the protocol defined grading system, the following guidelines will be used to 
describe severity.  
• Mild  – Events require minimal or no treatment and do not interfere with the participant’s daily 
activities.  
• Moderate – Events result in a low level of inconvenience or concern with the therapeutic measures.  Moderate events may cause some interference with fun ctioning. 
• Severe  – Events interrupt a participant’s usual daily activity and may require systemic drug 
therapy or other treatment. Severe events are usually potentially life-threatening or incapacitating. 
8.2.2 RELATIONSHIP TO STUDY AGENT  
The clinician’s assessment of an AE's relationship to the investigational device is part of the documentation process, but it is not a factor in determining what is or is not reported in the study.  If there 
is any doubt as to whether a clinical observation is an AE, the event should be reported.  All AEs must have their relationship to investigational device assessed.  In a clinical trial, the study product must always be suspect. To help assessment, the following guidelines are used.  
• Not Related  – relation to the device o r procedure can be excluded when: 
− The event is not a known side effect of the product category the device belongs to or of similar devices and procedures;  
− the event has no temporal relationship with the use of the investigational device or the procedures; 
− the serious event does not follow a known response pattern to the medical device (if the response 
pattern is previously known) and is biologically implausible 
− the discontinuation of medical device application or the reduction of the level of activation/exp osure - when clinically feasible – and reintroduction of its use (or increase of the 
level of activation/exposure), do not impact on the serious event; 
− the event involves a body-site or an organ not expected to be affected by [CONTACT_41491]; 
− the serious event can be attributed to another cause (e.g. an underlying or concurrent illness/ clinical condition, an effect of another device, drug, treatment or other risk factors). 
• Unlikely : the relationship with the use of the device seems not relevant and/or the event can be 
reasonably explained by [CONTACT_5748], but additional information may be obtained. 
• Possible : the relationship with the use of the investigational device is weak but cannot be ruled out 
completely.  Alternative causes are also possible (e.g. an underlying or concurrent illness/ clinical 
condition or/and an effect of another device, drug or treatment).  Cases were relatedness cannot be assessed or no information has been obtained should also be classified as possible. 
• Probable : the relationship with the use of the investigational device seems relevant and/or the event 
cannot reasonably be explained by [CONTACT_5748], but additional information may be obtained. 
• Causal relationship : the serious event is associated with the investigational dev ice or with 
procedures beyond reasonable doubt when: 
 Version 1.0 
Protocol  VI0121 29th January  2021  
Venus Concept    
CONFIDENTIAL  Page 26 of 40      1.0                                     
January 29th, 2021 
 − the event is a known side effect of the product category the device belongs to or of similar 
devices and procedures;  
− the event has a temporal relationship with investigational device use/application or procedures; 
− the event involves a body- site or organ th at the investigational device or procedures are applied to 
or the investigational device or procedures have an effect on;  
− the serious event follows a known response pattern to the medical device (if the response pattern is previously known); 
− the discontinuation of medical device application (or reduction of the level of activation/exposure) and reintroduction of its use (or increase of the level of activation/exposure), 
impact on the serious event (when clinically feasible);  
−  other possible causes (e.g. an underlying or concurrent illness/ clinical condition or/and an effect 
of another device, drug or treatment) have been adequately ruled out; 
− harm to the subject is due to error in use.  
8.2.3 EXPECTEDNESS  
Expected (anticipated) adverse reactions are AEs th at are common and known to occur for the 
investigational device being studied.  Expected adverse events in this study include discomfort or significant pain post- treatment, excessive skin redness (erythema) and/or swelling (edema), in -grown 
hairs, damage t o natural skin texture (crust, blister, burn), change of pi[INVESTIGATOR_371] (hyper- and hypo-
pi[INVESTIGATOR_371]), scarring. Treatment of hair -bearing areas in males may result in some damage to the 
follicles and subsequent loss of hair.  
An AE or suspected adverse rea ction is considered "unexpected" (unanticipated) if it is not known to 
occur for the investigational device being studied and at the specificity or severity that has been observed 
(AE not described into the Clinical protocol or User Manual). 
8.3 TIME PERIOD AND FREQUENCY FOR EVENT ASSESSMENT AND FOLLOW -
UP 
The occurrence of an AE or SAE may come to the attention of study personnel during study visits and 
interviews of a study participant presenting for medical care, or upon review by a study monitor. Al l AEs 
including local and systemic reactions not meeting the criteria for SAEs will be captured on the 
appropriate CRF. Information to be collected includes event description, time of onset, clinician’s 
assessment of severity, relationship to investigation al device and study procedures (assessed only by 
[CONTACT_8703] a diagnosis), and time of resolution/stabilization of the 
event. All AEs occurring while on study must be documented appropriately regardless of relationship. Al l 
AEs will be followed to adequate resolution.  
Any medical condition that is present at the time that the participant is screened will be considered as baseline and not reported as an AE. However, if the study participant’s condition deteriorates at any ti me 
during the study, it will be recorded as an AE. 
 Version 1.[ADDRESS_43533] all adverse events with start dates occurring any time after informed consent is 
obtained. At each study visit, the investigator will inquire study subjects about the occurrence of AE/SAEs since the l ast visit. All adverse events need to be followed until resolution or until study end, 
whichever occurs first.  
8.4 REPORTING PROCEDURES  
 
8.4.1 ADVERSE EVENT REPORTING  
All AEs will be recorded on the appropriate CRF and will include information about the s tart and stop 
dates, severity and relatedness. There should be an attempt to report a “diagnosis” rather than the individual signs, symptoms and abnormal laboratory values associated with the diagnosis. However, a diagnosis should be reported only if, in the Investigator’s judgment, it is relatively certain (i.e., definite or 
possible). Otherwise individual signs, symptoms and abnormal laboratory values should be reported as 
distinct adverse events.  
8.4.[ADDRESS_43534] be reported to the sponsor’s 
clinical research department immediately or within 24 hours by [CONTACT_41492] (see contact [CONTACT_2212]). 
 
  
 
A written report prepared by [CONTACT_079] (or designate) must follow within seven working days to the clinical monitor and should include a full description of the event and sequence. 
The study investigator shall complete a Serious Adverse Event / Serious Adverse Device Effect Form and 
submit to the study sponsor as soon as possible, but in no event later than [ADDRESS_43535].  
In accordance with t he requirements of Directive 93/42/EEC, and with MEDDEV 2.7/3, the following 
events are considered reportable events:  
1. any SAE (whether or not study procedure or device related), 
2. any Investigational Medical Device Deficiency that might have led to a SAE if a) suitable action 
had not been taken or b) intervention had not been made or c) if circumstances had been less fortunate, 
3. new findings/updates in relation to already reported events. 
 

 Version 1.0 
Protocol  VI0121 29th January  2021  
Venus Concept    
CONFIDENTIAL  Page 28 of 40      1.0                                     
January 29th, 2021 
 The sponsor will report the above-mentioned events to the Competent Authorities of all countries where 
the study is being conducted, within the following timelines: 
− Any SAE which indicates an imminent risk of death, serious injury, or serious illness AND that 
requires prompt remedial action for other patients/subjects, users or other persons or a new 
finding to it: immediately, but not later than 2 calendar days after awareness by [CONTACT_10400] a new 
reportable event or of new information in relation with an already reported event. 
− Any other reportable event or a new finding / update to it: immediately, but not later than 7 calendar days following the date of awareness by [CONTACT_41493]. 
 Reporting of the events listed above (under bullets 1- 3) to the ECs of the participating sites and to the 
other investigators will be performed according to country and/or site- specific requirements.  
 
8.4.[ADDRESS_43536] or Partner Pregnancy Outcome form within 10 business days. 
8.5 STUDY HALTING RULES  
The study may be halted at any time by [CONTACT_456], the EC / IRB, Competent Authorities due to safety concerns. Examples of findings that might trigger a safety review are the number of SAEs overall, the number of occurrences of a particular type of SAE, severe AEs/reactions, or increased frequency of 
events. If the study is halte d, the sponsor will immediately notify all investigational sites, the EC / IRB(s), 
the Competent Authorities of all countries where the study is being conducted. 
8.6 SAFETY OVERSIGHT  
Independent oversight is an important component to ensure human subjects' protection. Safety oversight 
will be under the direction of the sponsor and a medical monitor.  
[ADDRESS_43537] of the 
trial is in compliance with the currently appro ved protocol/amendment(s), with GCP, and with applicable 
regulatory requirement(s).  
• Monitoring for this study will be performed by [CONTACT_10404]. 
• Regular monitoring and an independent audit, if conducted, will be performed according to ISO [ZIP_CODE]:2011. 
 Version 1.0 
Protocol  VI0121 29th January  2021  
Venus Concept    
CONFIDENTIAL  Page 29 of 40      1.0                                     
January 29th, 2021 
 10 STATISTICAL CONSIDERATIONS   
 
10.1 STATISTICAL AND ANALYTICAL PLANS  
The Statistical and Analytical Plan (SAP) may be revised during the study to accommodate Clinical Trial 
Protocol Amendments and to make changes to adapt to unexpected issues in study execution and data that 
affect planned analyses. If revised, a formal SAP will be completed and issued prior to database lock and unblinding of the study data, if applicable.    
10.2 STATISTICAL HYPOTHESES  
The null and alternative hypotheses for the study’s primary, key secondary and safety endpoints are;  
• Primary Performance E ndpoint: 
o Null Hypothesis (Ho: μd = μpost – μpre = 0)  – There is no change (improvement) in 
GAIS mean score from baseline to [ADDRESS_43538]- treatment.  
o Alternative Hypothesis (Ha: μd = μpost – μpre ≠ 0)  – There is change (improvement) 
in GAIS mean score from baseline to [ADDRESS_43539] -treatment. The improvement 
of striae will be defined by [CONTACT_41494].   
• Secondary Performance Endpoint(s): 
o Null Hypothesis (Ho: μd = μpost – μpre = 0) – There is no change (improveme nt) in 
SSS mean score from baseline to [ADDRESS_43540]- treatment.  
Alternative Hypothesis (Ha: μd = μpost – μpre ≠ 0)  – There is change (improvement) 
in SSS mean score from baseline to [ADDRESS_43541] -treatment. The improvement of 
striae will be ev aluated by [CONTACT_41495] 5-point SSS.  
 
• Safety Endpoint: 
o Null Hypothesis (Ho: μd = μpost – μpre = 0)  – There is no difference in subjects’ 10 
cm discomfort/pain VAS score. 
Alternative Hypothesis (Ha: μd = μpost – μpre ≠ 0) – There is a difference in 
subjects’ 10 cm discomfort/pain VAS score. 
 
o Null Hypothesis (Ho: μd = μpost – μpre = 0)  – There is no difference in subjects’ 
tolerability score.  
Alternative Hypothesis (Ha: μd = μpost – μpre ≠ 0) – There is a difference in 
subjects’ tolerability score.  
 
10.3 ANALYSIS DATASETS  
Modified Intention- to-Treat Analysis Dataset will be used; Efficacy and safety analyses will be carried out 
on all subjects who received at least one treatment of Venus Viva™ MD fractional RF device and for whom 
at least one valid post- baseline efficacy an d safety evaluation were obtained.  
 Version 1.0 
Protocol  VI0121 29th January  2021  
Venus Concept    
CONFIDENTIAL  Page 30 of 40      1.0                                     
January 29th, 2021 
 10.4 DESCRIPTION OF STATISTICAL METHODS  
 
10.4.1 GENERAL APPROACH 
This is a prospective, single center, evaluator -blind study of the safety and performance of fractional 
radiofrequency (RF) for the treatment and reduction of facial acne scarring .   
All summary tables for quantitative parameters will display mean, standard deviation, median, range 
(minimum and maximum), percentages as well as number of missing data (if relevant). All summary tables 
for qualitative parameter s will display counts, percentages and number of missing data if relevant. Baseline 
data are defined as the last measurement, photograph or assessment performed before the first treatment on 
Visit 2.  
All statistical tests will be one -sided. The level of s tatistical significance for effectiveness analyses is 5% 
(α = 0.05) for all tests of differences. Where appropriate, Paired t -test and/or Wilcoxon Signed- Ranks Test 
for Matched Pairs will be used to compare the evaluations at the baseline and post treatment sessions. This 
test will enable us to accept or reject the null hypotheses. Rejection of null hypotheses will establish that:  
• The one-sided 95% confidence interval for the difference between the means excludes zero. 
• The two means are statistically signif icantly different at the 5% level ( P < 0.05) one -sided. 
Upon rejection of null hypotheses, further statistical test tools such as Confidence Interval and/or t -test will 
be used to determine the efficacy of the treatment. 
In other to accommodate imbalances of some baseline GAIS scores, covariate adjustment analysis may be 
performed in SAP to estimate adjusted treatment effects for the primary endpoint analysis.  
The assumption for the statistical test is that the paired differences of baseline and post treatment data are 
normally distributed.  
10.4.2 ANALYSIS OF THE PRIMARY EFFICACY ENDPOINT(S)  
The following will be considered for the analysis primary endpoint: 
Summary table for differences of baseline compared to [ADDRESS_43542] error.  The 
Global Aesthetic Improvement Scale (GAIS) is a 6 -level ordinal scale tool for assessing reduction of acne 
scarring.  
 
Bar, pie charts or graphs indicating scores, percentages or proportions of subjects with Global Aesthetic Improvement Scale (GAIS). 
 All statistical tests will be one -sided. The level of statistical significance for effectiveness analyses is 5% 
(α = 0.05) for all tests of differences. Where appropriate, Paired t -test and/or Wilcoxon Signed- Ranks Test 
for Matched Pairs will be used to compare the evaluations between baseline and [ADDRESS_43543] treatment assessments. Analysis of C ovariance (ANCOVA) may also be used where 
appropriate. Since the primary endpoint is based on achieving a fixed scale point on the GAIS, covariate 
 Version 1.[ADDRESS_43544] and/or Wilcoxon Signed- Ranks Test for Matched Pairs will enable us to accept or reject 
the null hypotheses. Rejection of null hypotheses will establish that: 
• The one-sided 95% confidence interval for the difference between the means excludes zero. 
• The two means are statistically significantly different at the 5% level ( P < 0.05) one -sided. 
Upon rejection of null hypotheses, further statistical test tools such as Confidence Interval and/or t -test will 
be used to test expected primary endpoint; that is alternative hypothesis that Ha > 1. This will be used to 
determine if the study meets the primary endpoi nt; GAIS score of > 0.75. 
GAIS scores of all subjects who received at least one treatment of Venus Viva™ MD fractional RF 
device and for whom at least one valid post- baseline GAIS assessment were obtained will be analyzed for 
the primary endpoint. Multiple imputation method or modelling of available data may be used for missing 
data as appropriate.  
10.4.3 ANALYSIS OF THE SECONDARY ENDPOINT(S)  
For the analysis of secondary endpoints, the following analysis will be considered:  
Summary tables for differences o f baseline compared to 6- week and baseline compared to [ADDRESS_43545] -
treatment of subjects’ assessment of satisfaction with the treatment using a Subject Satisfaction Scale will 
be displayed as mean difference, standard deviation and standard error.  The point level for each of these 
ordinal scale assessment tools will be put into consideration where applicable.  
 
Bar charts, pie chart, graphs or any other descriptive statistical displays indicating scores, percentages or 
proportions of Subjects’ assessment o f satisfaction with the treatment using a Subject Satisfaction Scale 
will be used to analyse efficacy.  
 All statistical tests that will be one -sided. The level of statistical significance for effectiveness analyses is 
5% (α = 0.05) for all tests of differe nces. Where appropriate, Paired t- test and/or Wilcoxon Signed-Ranks 
Test for Matched Pairs will be used to compare the evaluations score differences of baseline compared to 
6-week and baseline compared to 12- week post treatment assessment. Analysis of Covariance (ANCOVA) 
may also be used where appropriate.  
Subjects’ assessment of satisfaction with the treatment using a Subject Satisfaction Scale of all subjects who received at least one treatment of Venus Viva™ MD fractional RF device and for whom at least  one 
valid post -baseline assessment was obtained will be analysed for these secondary endpoints. Multiple 
imputation method or modelling of available data may be used for missing data as appropriate. 
10.4.4 SAFETY ANALYSES  
The safety analysis will be done by [CONTACT_10407] (AE), subjects 
completed 10 cm discomfort/pain VAS and Tolerability Scale as well as analysis of immediate and short 
 Version 1.0 
Protocol  VI0121 29th January  2021  
Venus Concept    
CONFIDENTIAL  Page 32 of 40      1.0                                     
January 29th, 2021 
 term response reports by [CONTACT_458] [INVESTIGATOR_39736] m his/her observation/examination of the treated area. 
Appropriate Medical Dictionary for Regulatory Activities (MedDRA) code will be used to describe all 
spontaneously reported or other study related adverse events. 
Summaries of spontaneously reported or other study related adverse events will be presented as:  
o Number (%) of subjects with any AE, 
o Number (%) of subjects with any serious adverse events (SAE), 
o Number (%) of subjects permanently withdrawn from treatment due to AE 
Summaries of analysis of immediate and short -term response reports by [CONTACT_458] 
[INVESTIGATOR_10378] a bar or pie chart as; 
o the overall frequency of subjects with each event (pain during treatment, hemorrhage, burn, 
erythema, edema, purpura) 
o Frequency of subjects with specific severity/intensity for each event using a 5 points scale: 1=none; 
2=trace; 3=moderate; 4=marked; 5=severe 
o The overall percentage or proportion of subject observed with marked or severe intensity of any event will be calculated and compared to those with none, trace or moderate severity/intensity with 
the aid of a bar or pie chart.  
The following will be considered for the analysis of 10 cm discomfort/pain VAS scores safety data:  
Summary table for differences of baseline and Visit 4 treatment 10 cm discomfort/pain VAS scores will be 
displayed as mean difference, standard deviation and standard error.  The 10 cm discomfort/pain VAS is a 11-level (0 to 10) ordinal scale tool for assessing pain. 
 
Bar, pie charts or graphs indicating scores, pe rcentages or proportions of subjects with Visit 4 treatment 
and baseline (Visit 2) VAS scores difference and Tolerability Scale will be used to analyse subjects’ tolerability of this treatment.  
 All statistical tests will be one -sided. The level of statist ical significance for effectiveness analyses is 5% 
(α = 0.05) for all tests of differences. Where appropriate, Paired t -test and/or Wilcoxon Signed- Ranks Test 
for Matched Pairs will be used to compare the difference between baseline and Visit [ADDRESS_43546] and/or Wilcoxon Signed- Ranks Test for Matched Pairs will enable us to accept or reject 
the null hypotheses. Rejection of null hypotheses will establish that: 
• The one-sided 95% confidence interval for the difference between the means excludes zero.  
• The two means are statistically significantly different at the 5% level ( P < 0.05) one -sided. 
Upon rejection of null hypotheses, further statistical test tools such as Confidence Interval and/or t -test will 
be used to test expected safety endpoint; that is alternative hypothesis, H a < 1.  
10.4.5 ADHERENCE  AND RETENTION ANALYSES  
 Version 1.0 
Protocol  VI0121 29th January  2021  
Venus Concept    
CONFIDENTIAL  Page 33 of 40      1.0                                     
January 29th, 2021 
 Adherence to the protocol will be assessed by [CONTACT_10408] (%) subjects’ data for each endpoint 
assessment that is not provided in subjects Case Report Forms. This will be further analysed as per frequency of each endpoint data that is not available due to loss to f ollow -up, discontinuation of the 
intervention or any other reason. 
10.4.6  BASELINE DESCRIPTIVE STATISTICS  
Subjects baseline scores of all endpoints ( GAIS , Subject Satisfaction Scale, Treatment Evaluation 
Questionnaire, VAS and Tolerability Scale) will be compared using descriptive statistics such as mean score, standard deviation, standard error, range and graphical presentations.  
10.4.7 PLANNED INTERIM A NALYSES  
 
No interim analysis is planned.   
 
[IP_ADDRESS] SAFETY REVIEW  
There will be no interim safety analysis during this study. However, this study may be temporarily 
suspended or prematurely terminated if there is sufficient reasonable cause.  
[IP_ADDRESS] EFFICACY REVIEW  
There will be no interim efficacy analysis during this study. However, this study may be temporarily 
suspended or prematurely terminated if there is sufficient reasonable cause.  
10.4.8 ADDITIONAL SUB -GROUP ANALYSES  
Primary or secondary endpoints may be further analyzed based on age, sex, race/ethnicity or other 
demographic characteristic(s).  
10.4.10  TABULATION OF INDIVIDUAL RESPONSE DATA  
Individual participant data will be listed by [CONTACT_10409].  
10.5 M EASURES TO MINIMIZE BIAS  
 
10.5 .1 ENROLLMENT/ RANDOMIZATION/ MASKING PROCEDURES  
At screening, once a subject has signed the informed consent, and inclusion/exclusion criteria has been 
met, a subject number will be assigned. This unique identifier will be used throughout the entire study and 
will be entered in the subject's CRF and for each treatment. Subjects are randomized; this is an open -
label, baseline -controlled, evaluator-blind multi- center study.  
10.5 .2 EVALUATION OF SUCCESS OF BLINDING  
Only the independent reviewers will be blinded. The treating physician and biostatistician or designated 
party (who conducts interim analysis) will not be blinded. 
 Version 1.0 
Protocol  VI0121 29th January  2021  
Venus Concept    
CONFIDENTIAL  Page 34 of 40      1.0                                     
January 29th, 2021 
 11 SOURCE DOCUMENTS AND ACCESS TO SOURCE DATA/DOCUMENTS  
Each participating site will maintain appropria te medical and research records for this trial, in compliance 
with ISO [ZIP_CODE]:2011, and regulatory and institutional requirements for the protection of confidentiality 
of participants. Each site will permit authorized representatives of the study sponsor, ethics committee and/or regulatory agencies to examine (and when permitted by [CONTACT_1289], to copy) clinical records 
for the purposes of quality assurance reviews, audits, and evaluation of the study safety, progress, and 
data validity.  
Source data are all information, original records of clinical findings, observations, or other activities in a 
clinical trial necessary for the reconstruction and evaluation of the trial. Examples of these original 
documents and data records include, but are not limited to, hospi[INVESTIGATOR_1097], clinical and office charts, laboratory notes, memoranda, participants' memory aids or evaluation checklists, pharmacy dispensing records, recorded audio tapes of counseling sessions, recorded data from automated instruments, copi[INVESTIGATOR_10379], microfiches, photographic 
negatives (where applicable), microfilm or magnetic media, x -rays, and participant files and records kept 
at the pharmacy, at the laboratories, and medico -technical departments involved in the clinical trial.  
It is acceptable to use CRFs as source documents. The following CRFs collected on no carbon required (NCR) paper will be source documents: 
• Subject self -reported VAS and Tolerability Scale, GAIS  and Subject Satisfaction Scale  
The remainder of the data collected from other sources.  
It is not acceptable for the CRF to be the only record of a subject’s participation in the study. This is to 
ensure that anyone who would access the patient medical record has adequate knowledge that the patient is participating in a clinical trial.  
12 QUALITY ASSURANCE AND QUALITY CONTROL  
Prior to any independent use of the Venus Viva™ MD device, study personnel, will receive proper 
training from the sponsor. Site personnel will be trained on the use of the device prior to study initiation at the site.  Additional training requirements will be discussed during study initiation and will include site responsibilities, and study documentation. In addition, the sponsor will provide protocol specific training 
for the site. The site will document which individual has been assigned to a specific task and will ensure 
that appropriate training has occurred for that task.  
Regular monitoring and an independent audit, if conducted, must be performed according to ISO 
[ZIP_CODE]:2011. See also Section 9, Clinical Monitoring. 
Quality control (QC) procedures will be implemented beginning with the data entry system and data QC 
checks that will be run on the database will be generated.  Any missing dat a or data anomalies will be 
communicated to the site(s) for clarification/resolution.  
Monitors will verify that the clinical trial is conducted, and data are generated, documented (recorded), and reported in compliance with the protocol, GCP, and the appli cable regulatory requirements.  
 Version 1.[ADDRESS_43547] access to all trial related sites, source data/documents, and 
reports for the purpose of monitoring and auditing by [CONTACT_456], and inspection by [CONTACT_3482].  
13 ETHICS/PROTECTION OF HUMAN SUBJECTS  
 
13.[ADDRESS_43548] version of the 
Declaration of Helsinki (2013), ISO [ZIP_CODE]:2011 (Clinical investigation of medical devices for human 
subjects - Good clinical practice), FDA and any other applicable country’s ethical policy statement, 
whichever provides the higher level of protection to human subjects. 
13.[ADDRESS_43549]  
The protocol, informed cons ent form(s), recruitment materials, and all participant materials will be 
submitted to the EC / IRB for review and approval. Approval of both the protocol and the consent form must be obtained before any participant is enrolled. Any amendment to the protoc ol will require review 
and approval by [CONTACT_1383] / IRB before the changes are implemented to the study. All changes to the consent form will be EC / IRB approved; a determination will be made by [CONTACT_41496] -consented.  
13.3 INFORMED CONSENT PROCESS  
 
13.3.1 CONSENT/ASSENT AND O THER INFORMATIONAL DOCUMENTS PROVIDED 
TO PARTICIPANT S 
Informed consent is required for all subjects in a study.  In obtaining and documenting informed consent, 
the investigator  should comply with applicable regulatory requirements and should adhere to ISO 
[ZIP_CODE]:[ADDRESS_43550] version of the Declaration of Helsinki (2013).  Prior to the beginning of a 
trial, the investigator should have the EC / IRB's written approval for the protocol and the written 
informed consent forms(s) and any other written information to be provided to the participants.  Consent forms describing in detail the investigational medical device, study procedures, and risks are given to the participant a nd written documentation of informed consent is required prior to starting intervention with 
investigational medical device.  
13.3.2 CONSENT PROCEDURES AND DOCUMENTATION 
Informed consent is a process that is initiated prior to the individual’s agreeing to p articipate in the study 
and continues throughout the individual’s study participation. Extensive discussion of risks and possible benefits of participation will be provided to the participants and their families.  Consent forms will be EC or IRB approved and the participant will be asked to read and review the document. The investigator will 
explain the research study to the participant and answer any questions that may arise. All participants will 
receive a verbal explanation in terms suited to their compr ehension of the purposes, procedures, potential 
risks of the study and their rights as research participants.  Participants will have the opportunity to 
 Version 1.[ADDRESS_43551] by [CONTACT_3486], their staff, and the 
sponsor(s) and their agents. This confidentiality is extended to cover testing of biological samples in 
addition to the clinical information rela ting to participants. Therefore, the study protocol, documentation, 
data, and all other information generated will be held in strict confidence. No information concerning the study or the data will be released to any unauthorized third party without prior written approval of the 
sponsor. 
The study monitor, other authorized representatives of the sponsor, representatives of the EC / IRB and 
Competent Authorities or device company supplying study product may inspect all documents and 
records required to be ma intained by [CONTACT_093], including but not limited to, medical records 
(office, clinic, or hospi[INVESTIGATOR_307]) and pharmacy records for the participants in this study. The clinical study site 
will permit access to such records.  
The study participant’s contact i nformation will be securely stored at each clinical site for internal use 
during the study. At the end of the study, all records will continue to be kept in a secure location for as long a period as dictated by [CONTACT_456], and any applicable regulations (refer to section 14.2 STUDY RECORDS RETENTION).  
Study participant research data, which is for purposes of statistical analysis and scientific reporting, will be transmitted to and stored at the sponsor’s office. This will not include the participant’s cont act or 
identifying information. Rather, individual participants and their research data will be identified by a 
unique study identification number. The study data entry and study management systems used by [CONTACT_41497]’s research staff will be secured and password protected.  At the end of the study, all study databases will be de-identified and archived by [CONTACT_456]. 
13.4.[ADDRESS_43552] -treatment changes in skin morphology.  
Access to stored samples will be limited to the principal investigator’s staff or designated lab and will be stored securely. Only investigators will have access to the samples. The sponsor will not have access to the samples, only the data generated from the samples.  
 Version 1.0 
Protocol  VI0121 29th January  2021  
Venus Concept    
CONFIDENTIAL  Page 37 of 40      1.0                                     
January 29th, 2021 
 Disposition at the completion of the study: The investigator will store all the samples upto [ADDRESS_43553] KEEPI[INVESTIGATOR_1645]  
 
14.1 DATA COLLECTION AND MANAGEMENT RESPONSIBILITIES  
Data collection is the responsibility of the clinical trial staff at the site under the supervision of the site Principal Investigator.  The investigator is responsible for ensuring the accuracy, completeness, legibility, and timeliness of the data reported.  
All source documents should be completed in a neat, legible manner to ensure accurate interpretation of data.  Black ink is required to ensure clarity of reproduced copi[INVESTIGATOR_014]. When making changes or corrections, cross out the original entry with a single line, and initial and date the change.  DO NOT ERASE, OVERWRITE, OR USE CORRECTION FLUID O R TAPE ON THE ORIGINAL.  
Copi[INVESTIGATOR_41481].  Data reported in the CRF derived from source documents should be consistent with the source documents or the discrepancies should be explained and captured in 
a progress note and maintained in the participant’s official study record.  Self- reported subject data and 
investigator CRF reported data recorded on the copy CRF page is permitted.  The original form will be 
collected by [CONTACT_10416].  
Clinical data (including AEs, concomitant medications, and expected adverse reactions data) and clinical laboratory data from paper CRFs will be entered directly ont o paper CRFs from the source documents and 
will be collected by [CONTACT_4530]. 
14.2 STUDY RECORDS RETENTION  
Study documents, including copi[INVESTIGATOR_10381], signed informed consent forms, photographs 
(where applicable), laboratory results, medical  records, data clarification forms and regulatory documents, 
should be retained for a minimum period of 5 years after the end of the clinical investigation, or longer if 
required by [CONTACT_1295]. The investigator should take measures to prevent acciden tal or early 
destruction of the study related materials.  No records will be destroyed without the written consent of the 
sponsor, if applicable.  It is the responsibility of the sponsor to inform the investigator when these 
documents no longer need to be retained.  
14.3 PROTOCOL DEVIATIONS  
A protocol deviation is any instance(s) of failure to follow, intentionally or unintentionally, the requirements of the Clinical Investigation Plan. Applicable definition follow:  
 Version 1.0 
Protocol  VI0121 29th January  2021  
Venus Concept    
CONFIDENTIAL  Page 38 of 40      1.0                                     
January 29th, 2021 
 − Major deviation: CIP deviations that can have affected the rights, safety or well -being of the subject 
or the scientific integrity of the clinical investigation.  
− Minor deviation: CIP deviations that do NOT have affected the rights, safety or well- being of the 
subject or the scientific integrity o f the clinical investigation.  
The noncompliance may be either on the part of the participant, the investigator, or the study site staff.  
As a result of deviations, corrective actions are to be developed by [CONTACT_3483].  
These practices are consistent with ISO [ZIP_CODE]:2011: 
• 4.5 Compliance with Protocol, sections 4.5.1, 4.5.2, and 4.5.3 
• 5.1 Quality Assurance and Quality Control, section 5.1.1 
• 5.[ADDRESS_43554] been met: 
a. The Investigator, the Sponsor and Statistician have approved the protocol amendment and 
b. The responsible EC and Competent Authority has reviewed and approved the protocol change. 
Under emergency circumstances, deviations from the CIP to protect the rights, safety and well-being of 
human subjects may proceed without prior approval of the sponsor and the EC.  Such deviations shall be 
documented and reported to the sponsor and the EC as soon as possible.  
A corrective action will be taken: documenting the deviation (source document, log, CRF as relevant)  
including its reasons of occurrence and corrective actions to be taken to further avoid reoccurrence of it 
and properly reporting. The investigator as well as site personnel will be trained in order to avoid any 
major protocol deviation in the future.  
Failure to comply with this clinical investigation plan and/or EC, Competent Authorities, any local 
requirement will result in corrective actions and could result in the removal of the investigator from the study. 
It is the responsibility of the site to use c ontinuous vigilance to identify and report deviations promptly to 
study sponsor and to EC (if required by [CONTACT_1295]).  All deviations must be addressed in study 
source documents.  The site PI/study staff is responsible for knowing and adhering to their EC requirements.  
14.4 PUBLICATION AND DATA SHARING POLICY  
The International Committee of Medical Journal Editors (ICMJE) member journals have adopted a 
clinical trials registration policy as a condition for publication. The ICMJE defines a clinical trial as any 
research project that prospectively assigns human su bjects to intervention or concurrent comparison or 
control groups to study the cause -and-effect relationship between a medical intervention and a health 
outcome. Medical interventions include drugs, surgical procedures, devices, behavioral treatments, process-of-care changes, and the like.  Health outcomes include any biomedical or health -related 
 Version 1.[ADDRESS_43555] of 2007, requires that all clinical trials be registered in a public trials registry such as ClinicalTrials.gov, which is sponsored by [CONTACT_10418]. Other biomedical journals are considering adopting similar policies.  The Declaration of 
Helsin ki current revision (2013) states that every research study involving human subjects must be 
registered in a publicly accessible database before recruitment of the first subject (sec.35).  
The sponsor or its designee will register the VI1218 study into a publicly accessible database.  All data generated from this study are the property of Venus Concept Ltd and shall be held in strict confidence along with all information furnished by [CONTACT_10419]. 
Independent analysis and/or publication of these data by [CONTACT_10420]/her staff 
are not permitted without prior written consent of Venus Concept Ltd.  Written permission to the Investigator will be contingent on the review by [CONTACT_41498]. In all cases, the parties agree to submit all manuscripts or abstracts to all other parties at least [ADDRESS_43556], Falto -Aizpurua LA, Nouri K. Use of radiofrequency in cosmetic 
dermatology: focus on nonablative treatm ent of acne scars. Clinical, Cosmetic and Investigational 
Dermatology. 2014;7:335–9.  
 Version 1.0 
Protocol  VI0121 29th January  2021  
Venus Concept    
CONFIDENTIAL  Page 40 of 40      1.0                                     
January 29th, 2021 
 2.  O’Daniel TG. Multimodal management of atrophic acne scarring in the aging face. Aesthetic Plast 
Surg. 2011 Dec;35(6):1143–50.  
3.  Omi T, Sato S, Kaminaka C, Yamamoto  Y, Kawana S, Naito Z. A Histological Study on the 
Treatment of Acne Scars with Fractional Radiofrequency: Preliminary Findings. Clin Exp Dermatol 
Res. 2014;5(1).  
4.  de Felipe I, Del Cueto SR, Pérez E, Redondo P. Adverse reactions after nonablative radiofrequency: 
follow-up of 290 patients. J Cosmet Dermatol. 2007 Sep;6(3):163–6.  
 
APPENDIX  
 
Version  Date  Significant Revisions  
   
   
 